Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

  • Inhibrx Inc INBX announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD).
  • AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. 
  • Treatment was well tolerated, with no severe or serious adverse events related to the study drug. 
  • Related: Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors.
  • Drug-related adverse events were predominantly mild, and those few that were moderate in severity were all transient and reversible, with minimal or no symptomatic care. 
  • No safety-related or PK/PD-related signs of neutralizing anti-drug antibodies were observed.
  • Data from the multiple ascending dose cohorts of INBRX-101 at 40, 80, and 120 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels.
  • The current standard of care, plasma-derived AAT, dosed once weekly at 60 mg/kg, achieves a Cavg of functional AAT of 17.8 µM over the weekly dosing interval. 
  • INBRX-101 achieved a mean Cavg of functional AAT of 40.4 µM over the 21-day dosing interval following the third 80 mg/kg dose.
  • Price Action: INBX shares are down 10.50% at $15.16 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!